Administering the psychedelic drug ibogaine has shown promise in slowing down brainwaves among individuals with traumatic brain injury, possibly elucidating its efficacy in treating post-traumatic stress disorder (PTSD). Derived from the iboga plant, ibogaine has demonstrated the potential to alleviate PTSD symptoms by influencing brainwave activity.
In a recent study conducted by Jennifer Lissemore and her team at Stanford University, brain scans of 30 male participants with traumatic brain injury, most of whom also suffered from PTSD, were analyzed following ibogaine treatment. The participants received a dosage of 12 milligrams per kilogram of body weight over a five-day period at a treatment facility in Mexico. EEG recordings were taken before the therapy, 3.5 days post-treatment, and one month later to monitor changes in brainwave patterns.
The analysis revealed intriguing findings regarding brainwave alterations post-ibogaine therapy. Notably, faster brainwaves exhibited decreased strength, while slower brainwaves showed an increase in intensity. For instance, gamma waves, the fastest brainwave type, experienced a significant decrease in strength post-treatment, particularly in regions at the back of the brain. Conversely, theta waves, associated with slower brain activity, displayed a noticeable increase in intensity shortly after ibogaine administration.
The observed slowing of brainwaves post-ibogaine treatment aligns with the improvement in PTSD symptoms among the majority of participants. This deceleration in brain activity appears to correlate with the alleviation of hyperarousal, hypervigilance, and other PTSD-related symptoms. Moreover, the temporary surge in theta waves hints at ibogaine’s potential to induce neuroplasticity, facilitating the brain’s ability to rewire itself for enhanced mental well-being.
While the study sheds light on the correlation between ibogaine-induced brainwave alterations and PTSD symptom improvement, uncertainties remain regarding the precise mechanisms through which ibogaine exerts its effects. The absence of a control group complicates the interpretation of results, making it challenging to isolate the impact of ibogaine from other treatment components such as therapy. Nevertheless, these findings mark a crucial initial step in unraveling the therapeutic potential of ibogaine in addressing PTSD.
Conor Murray from the University of California, Los Angeles, underscores the normalization effect of ibogaine on the brain, providing participants with a sense of tranquility and mental peace. The drug’s ability to calm the restless brain and potentially promote neuroplasticity signifies a promising avenue for further research into its therapeutic mechanisms. Ibogaine’s capacity to modulate brainwave activity presents a novel approach to addressing PTSD, emphasizing the need for comprehensive investigations into its clinical applications.
Key Takeaways:
– Ibogaine demonstrates the potential to alleviate PTSD symptoms by modulating brainwave activity, particularly by slowing down faster brainwaves and increasing slower brainwaves.
– The observed changes in brainwave patterns post-ibogaine treatment suggest a link between brainwave modulation and the mitigation of hyperarousal and other PTSD symptoms.
– While the study provides valuable insights into the effects of ibogaine on brain activity, further research with control groups is essential to elucidate the specific mechanisms underlying its therapeutic actions.
– Ibogaine’s ability to induce neuroplasticity and promote a sense of mental peace highlights its promise as a novel treatment approach for PTSD and warrants continued exploration in clinical settings.
Read more on newscientist.com